| Market Capitalization (Millions $) |
94 |
| Shares
Outstanding (Millions) |
32 |
| Employees |
14 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-12 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Anixa Biosciences Inc
Anixa Biosciences Inc is a publicly held biotechnology company that specializes in cancer treatment and detection technologies. Founded in 1982, the company is headquartered in San Jose, California and operates with key partnerships in academic research institutions and hospitals around the United States.
The mission of Anixa Biosciences Inc is to develop and market innovative cancer diagnostics and therapies that improve patient outcomes and reduce healthcare costs. The company's product focus is on developing diagnostic tests and immunotherapies for cancer detection and treatment.
One of Anixa's most promising products is its liquid biopsy technology, Cchek, which is a non-invasive blood test for early detection of cancer. Cchek utilizes artificial intelligence and machine learning algorithms to analyze circulating tumor cells (CTCs) and other biomarkers in a patient's blood sample to accurately identify early-stage cancer.
Anixa's additional cancer therapies in development include:
- CAR-T therapy for ovarian cancer
- vaccine for breast cancer
- prostate cancer drug
The company has obtained several patents for its cancer detection and therapy technologies and collaborations with leading academic institutions like Cleveland Clinic and The Moffitt Cancer Center.
Anixa is led by an experienced team of cancer researchers and executives that aim to bring their innovative cancer therapies and diagnostic tests to market. The company is publicly traded on the NASDAQ under the ticker symbol ANIX.
Company Address: 3150 Almaden Expressway San Jose 95118 CA
Company Phone Number: 708-9808 Stock Exchange / Ticker: NASDAQ ANIX
|
68.12%